NCT01873248View on ClinicalTrials.gov

Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 26, 2013

Primary Completion Date

June 16, 2017

Study Completion Date

June 16, 2017

Conditions
Neuroendocrine Tumors
Interventions
DRUG

68Ga-DOTATATE

68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.

Trial Locations (1)

90095

University of California Los Angeles, Nuclear Medicine Clinic of the Department of Molecular and Medical Pharmacology, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER

NCT01873248 - Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective | Biotech Hunter | Biotech Hunter